Research graph
References from Multidisciplinary treatment incorporating autologous DC-CIK cell therapy induces long-term survival in advanced pancreatic cancer: a case report. Local targets link to admitted publications; unresolved targets remain external evidence.
Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future
10.3322/caac.70035 · 2026 · External reference
NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: A systematic review and meta-analysis
10.1001/jamanetworkopen.2023.50756 · 2024 · External reference
Advances in the management of pancreatic cancer: Current strategies and emerging therapies
10.3390/ijms26157055 · 2025 · External reference
Efficacy and safety of combination therapy with immune checkpoint inhibitors and chemotherapy with gemcitabine and nab-paclitaxel in pancreatic cancer: A systematic review
10.1002/cam4.71637 · 2026 · External reference
Neoantigen T-cell receptor gene therapy in pancreatic cancer
10.1056/nejmc2208623 · 2022 · External reference
Hurdles race for CAR T-cell therapy in digestive tract cancer
10.1111/imr.13273 · 2023 · External reference
Immunosuppressive tumor microenvironment shape pancreatic cancer unresponsive to current immunotherapies
10.5306/wjco.v17.i2.114423 · 2026 · External reference
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer
10.1038/s43018-022-00500-z · 2023 · External reference
Synergistic therapy for pancreatic cancer by deactivating cancer-associated fibroblasts and driving T-cell migration into tumor microenvironment using nanochaperone delivery system
10.1016/j.bioactmat.2025.06.010 · 2025 · External reference
Epigenetic modulation to overcome immune suppression in pancreatic cancer
10.1186/s13148-026-02081-5 · 2026 · External reference
Non-genetically modified adoptive cell therapies for solid tumors: Current landscape and future challenges
10.1007/s00262-025-04274-y · 2026 · External reference
Combined immunotherapy with dendritic cells and cytokine-induced killer cells for solid tumors: a systematic review and meta-analysis of randomized controlled trials
10.1186/s12967-024-05940-y · 2024 · External reference
Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer: A meta-analysis
10.1097/md.0000000000024519 · 2021 · External reference
Clinical applications of dendritic cells-cytokine-induced killer cells mediated immunotherapy for pancreatic cancer: an up-to-date meta-analysis
10.2147/ott.s143382 · 2017 · External reference
Efficacy of DC-CIK-based immunotherapy combined with chemotherapy in the treatment of intermediate to advanced non-small cell lung cancer
2021 · External reference
Requirement for a standardised definition of advanced gastric cancer
10.3892/ol.2013.1672 · 2014 · External reference
Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer
10.1038/s41572-026-00699-6 · 2026 · External reference
Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer
10.1016/s0889-8588(15)00091-x · 2026 · External reference
Preclinical evaluation of DC-CIK cells as potentially effective immunotherapy model for the treatment of glioblastoma
10.1038/s41598-024-84284-5 · 2025 · External reference
Cytokine-induced killer cells co-cultured with non-cell derived targeting peptide-loaded dendritic cells induce a specific antitumor response
10.1080/15384047.2018.1564561 · 2019 · External reference
Therapeutic potential of cytokine-induced killer cell therapy for renal cell carcinoma and prostate cancer
10.1186/s12964-026-02770-x · 2026 · External reference
Mechanisms and clinical advancements of cell-based immunotherapies in non-small cell lung cancer: an integrated perspective
10.3389/fimmu.2025.1633100 · 2025 · External reference
Cytokine-induced killer cell therapy for advanced pancreatic adenocarcinoma: A case report and review of the literature
10.3892/ol.2013.1200 · 2013 · External reference
Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer
10.1007/s00262-014-1566-3 · 2014 · External reference
Recent advances and challenges in the treatment of advanced pancreatic cancer: An update on completed and ongoing clinical trials
10.3390/cancers17081319 · 2025 · External reference
NALIRIFOX, FOLFIRINOX, and gemcitabine with nab-paclitaxel as first-line chemotherapy for metastatic pancreatic cancer: A systematic review and meta-analysis
10.1001/jamanetworkopen.2023.50756 · ExternalCitation · doi-reference
Efficacy and safety of combination therapy with immune checkpoint inhibitors and chemotherapy with gemcitabine and nab-paclitaxel in pancreatic cancer: A systematic review
10.1002/cam4.71637 · ExternalCitation · doi-reference
Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer
10.1007/s00262-014-1566-3 · ExternalCitation · doi-reference
Non-genetically modified adoptive cell therapies for solid tumors: Current landscape and future challenges
10.1007/s00262-025-04274-y · ExternalCitation · doi-reference
Synergistic therapy for pancreatic cancer by deactivating cancer-associated fibroblasts and driving T-cell migration into tumor microenvironment using nanochaperone delivery system
10.1016/j.bioactmat.2025.06.010 · ExternalCitation · doi-reference
Daraxonrasib in previously treated advanced RAS-mutated pancreatic cancer
10.1016/s0889-8588(15)00091-x · ExternalCitation · doi-reference
Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer
10.1038/s41572-026-00699-6 · ExternalCitation · doi-reference
Preclinical evaluation of DC-CIK cells as potentially effective immunotherapy model for the treatment of glioblastoma
10.1038/s41598-024-84284-5 · ExternalCitation · doi-reference
Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer
10.1038/s43018-022-00500-z · ExternalCitation · doi-reference
Neoantigen T-cell receptor gene therapy in pancreatic cancer
10.1056/nejmc2208623 · ExternalCitation · doi-reference
Cytokine-induced killer cells co-cultured with non-cell derived targeting peptide-loaded dendritic cells induce a specific antitumor response
10.1080/15384047.2018.1564561 · ExternalCitation · doi-reference
Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer: A meta-analysis
10.1097/md.0000000000024519 · ExternalCitation · doi-reference
Hurdles race for CAR T-cell therapy in digestive tract cancer
10.1111/imr.13273 · ExternalCitation · doi-reference
Therapeutic potential of cytokine-induced killer cell therapy for renal cell carcinoma and prostate cancer
10.1186/s12964-026-02770-x · ExternalCitation · doi-reference
Combined immunotherapy with dendritic cells and cytokine-induced killer cells for solid tumors: a systematic review and meta-analysis of randomized controlled trials
10.1186/s12967-024-05940-y · ExternalCitation · doi-reference
Epigenetic modulation to overcome immune suppression in pancreatic cancer
10.1186/s13148-026-02081-5 · ExternalCitation · doi-reference
Clinical applications of dendritic cells-cytokine-induced killer cells mediated immunotherapy for pancreatic cancer: an up-to-date meta-analysis
10.2147/ott.s143382 · ExternalCitation · doi-reference
Advances in pancreatic cancer early diagnosis, prevention, and treatment: The past, the present, and the future
10.3322/caac.70035 · ExternalCitation · doi-reference
Mechanisms and clinical advancements of cell-based immunotherapies in non-small cell lung cancer: an integrated perspective
10.3389/fimmu.2025.1633100 · ExternalCitation · doi-reference
Recent advances and challenges in the treatment of advanced pancreatic cancer: An update on completed and ongoing clinical trials
10.3390/cancers17081319 · ExternalCitation · doi-reference
Advances in the management of pancreatic cancer: Current strategies and emerging therapies
10.3390/ijms26157055 · ExternalCitation · doi-reference
Cytokine-induced killer cell therapy for advanced pancreatic adenocarcinoma: A case report and review of the literature
10.3892/ol.2013.1200 · ExternalCitation · doi-reference
Requirement for a standardised definition of advanced gastric cancer
10.3892/ol.2013.1672 · ExternalCitation · doi-reference
Immunosuppressive tumor microenvironment shape pancreatic cancer unresponsive to current immunotherapies
10.5306/wjco.v17.i2.114423 · ExternalCitation · doi-reference
